Fortis Healthcare Limited continues to demonstrate robust operational and financial momentum, driven by sustained growth in its hospital segment and a steady recovery in its diagnostics arm, Agilus Diagnostics. Axis Direct believes the company is well positioned to capitalize on India’s expanding healthcare demand through strategic capacity additions and operational efficiencies. With rising occupancy rates, improving revenue per occupied bed (ARPOB), and strong margin expansion, Fortis is transitioning into a more profitable growth phase. The company’s disciplined expansion strategy and improving specialty mix are expected to enhance profitability further, supporting Axis Direct’s BUY call with a target price of Rs 1,038.

Fortis Healthcare: A Leading Integrated Healthcare Platform

Fortis Healthcare Limited stands among India’s most prominent private healthcare providers. The company operates an integrated healthcare delivery model spanning hospitals, diagnostics centers, and day-care specialty facilities. Its network currently includes 36 healthcare facilities across 12 states, supported by over 6,000 operational hospital beds and nearly 400 diagnostic laboratories.

This extensive footprint positions Fortis as a key beneficiary of India’s expanding healthcare demand, particularly as urban populations increasingly seek high-quality tertiary and quaternary medical services.

The company’s diversified service portfolio also provides resilience against cyclical fluctuations, enabling stable revenue streams across multiple healthcare verticals.

Hospital Segment Driving Strong Revenue Growth

The hospital division continues to be Fortis Healthcare’s primary growth engine. During the first nine months of FY26, the company reported consolidated revenue of Rs 6,763 crore, reflecting 17.1% year-on-year growth.

This expansion was largely driven by strong patient volumes and higher complexity procedures across Fortis hospitals.

Key operational metrics illustrate the improving healthcare demand:

Average occupancy rate: 69%

Average Revenue Per Occupied Bed (ARPOB): Rs 70,500

Hospital segment revenue growth: 19.1% YoY

Segment profitability has also improved considerably. Hospital EBITDA margins expanded to 22.2%, compared with 20.0% in the previous year, highlighting the company’s improving operating leverage.

The combination of higher occupancy, richer case mix, and improved pricing power continues to strengthen the hospital segment’s profitability profile.

Agilus Diagnostics Showing Signs of Strong Recovery

Fortis’ diagnostics business, rebranded as Agilus Diagnostics Limited, is witnessing renewed growth momentum.

Following its rebranding from SRL Diagnostics, the division has undertaken aggressive network expansion and operational restructuring.

During FY26 so far:

Diagnostic revenue increased 7.7% YoY to Rs 1,139 crore

Operating EBITDA rose to Rs 275 crore from Rs 185 crore

EBITDA margin expanded sharply to 24.1% from 17.5%

The business conducted 30.7 million diagnostic tests, compared with 29.6 million tests in the previous year.

Fortis has strengthened the diagnostic network through the addition of more than 550 customer touchpoints, along with 8 new stat laboratories and 9 hub laboratories.

These initiatives are improving accessibility in key metropolitan clusters and emerging micro-markets, helping Agilus regain competitive momentum in India’s fast-growing diagnostics sector.

Cluster-Based Expansion Strategy Strengthens Capacity

Fortis Healthcare continues to expand capacity through a carefully structured cluster-based growth strategy.

The company has added approximately 750 operational beds year-to-date, combining acquisitions and leased hospital properties.

One notable transaction includes the Rs 430 crore acquisition of People Tree Hospitals, which provides Fortis with a 125-bed presence in Bengaluru, a strategically important healthcare market.

The acquisition also offers expansion potential to more than 300 beds, thanks to available adjacent land.

Beyond acquisitions, Fortis is also investing in specialized healthcare services. The launch of Adayu, a dedicated mental health facility, represents a strategic step toward expanding the company’s clinical capabilities in high-demand specialties.

Looking ahead, the company plans to add over 3,200 beds over the next three years, largely through brownfield expansions, which typically offer faster execution and superior capital efficiency.

Improving Case Mix to Drive Higher Profitability

Fortis Healthcare’s profitability outlook is supported by a shift toward high-value medical procedures.

Management expects hospital revenue growth in the second half of FY26 to remain strong, supported by:

4–6% expected increase in ARPOB

Greater share of complex procedures

Higher demand for oncology and robotic surgeries

This evolving case mix is particularly beneficial because specialized treatments typically command higher margins and better pricing power.

As operational efficiencies improve across the network, EBITDA margins are expected to exceed the FY26 guidance range of 22–22.5%.

Over the medium term, Fortis aims to achieve EBITDA margins of around 25%, which would place the company among the most profitable healthcare providers in India.

Valuation Snapshot and Financial Outlook

Fortis Healthcare’s improving financial performance is reflected in its forward earnings trajectory.

The company currently trades at approximately 27x and 23x EV/EBITDA for FY27E and FY28E, respectively.

While the valuation appears premium relative to historical levels, analysts argue that Fortis deserves a higher multiple due to:

strong structural healthcare demand

rising operating leverage

consistent margin expansion

capacity growth across key urban markets

Key Market Data and Investment Levels

These levels suggest moderate upside potential over the next 6–9 months, provided the company continues to deliver strong operational results.

Investment Verdict

Axis Direct maintains a BUY recommendation on Fortis Healthcare Limited.

The brokerage believes the company is entering a phase of sustainable earnings expansion, supported by:

strong hospital segment growth

recovery in diagnostics

disciplined capacity expansion

improving specialty mix

With operational efficiency improving and margins expanding steadily, Fortis Healthcare appears well positioned to benefit from India’s long-term healthcare demand.

Investors with a medium-term horizon may consider the stock for potential upside toward Rs 1,038.